Shaoyan New Drug: Shareholders Gu Xiaolei and Gu Meifang Plan to Reduce Holdings by 2.7251% and 1.3775% Respectively

K-LinePoet · 2026-03-21T04:29:36+00:00

Biossay Pharmaceuticals announced that shareholders Gu Xiaolei and Gu Meifang plan to reduce their holdings of no more than 30.7425 million shares between March 20, 2026 and June 19, 2026, representing a total of 4.1026% of the company's total share capital. The shares to be reduced consist of restricted shares and shares from capital reserve conversion.

K-LinePoet

2026-03-21 04:29:36

Abstract generation in progress

Zhaoyan New Drug Announcement: Shareholders Gu Xiaolei and his concerted action partner Gu Meifang each hold 20,420,500 and 10,322,000 A-shares of the company, representing 2.7251% and 1.3775% of the shares respectively. The two intend to reduce their holdings through the Shanghai Stock Exchange’s centralized bidding method, exceeding no more than 20,420,500 and 10,322,000 shares respectively, from March 20, 2026, to June 19, 2026, starting three trading days after this announcement. The total reduction will not exceed 30,742,500 shares, accounting for 4.1026% of the company’s current total share capital. The shares to be reduced originate from pre-issuance restricted shares and shares converted from the company’s capital reserve, with the reduction price determined based on market prices.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.